According to a recent press release, the University of Texas at Arlington‘s research projects will be further promoted and commercialized through an evolving partnership between the Fort Worth-based technology group Tech Fort Worth and the University.
The TechFW start-up initiative will offer educational services and training to the university staff and employees while also providing access to the TechFW networking platform to researchers and faculty members at UT Arlington to approach and maintain connections with the North Texas entrepreneurial community.
Extensive research and scientific development projects grew at a tremendous rate in the past few years at UT Arlington, with over $77.7 million spent during the fiscal year August 2012 to August 2013.
“Research and technologies developed by a major research institution like UT Arlington have the power to generate business and strengthen the region’s economy. This collaboration with TechFW will be an important catalyst for helping the private sector capitalize on UT Arlington innovation to benefit a broad range of businesses and industries.”
Executive director of TechFW Darlene Boudreaux is encouraged by the new relationship and hopes that this partnership will open the door for new opportunities for her organization and other clients associated with it, commenting:
“There will be plenty of economic opportunities for our existing clients to access the tremendous resources available at UT Arlington. We look forward to teaming with UT Arlington entities like the UT Arlington Research Institute and the Shimadzu Institute for Research Technology, and with professors who have secured numerous national grants.”
As part of this collaboration and partnership, researchers from UT Arlington will have access to various TechFW institutions, such as 1120 South Freeway, Fort Worth’s James E. Guinn School facility, and Acceleration Lab at University of North Texas Health Science Center at 3400 Camp Bowie Blvd.
In addition, core programs will also be available to UT Arlington researchers, including the Cowtown Angels Network, Tech Nest, the Acceleration Program, Incubation Workshop, and TechFW’s online radio show (biweekly) Tech Talk – Texas Style.
In addition, the two institutes are also collaborating on establishing a new program, which they called Breakthrough at UT Arlington. The aim of this program is to analyze the future economical and commercial value of research projects to include investors and stakeholders in the process.
“Breakthrough will afford up to 20 UT Arlington researchers a year the opportunity to better focus their discovery or invention for the investor community. Researchers and professors will gain insight into how business people think and how to move their concepts closer toward market applications.”
The organization emerged as a non-profit organization in 1998 to explore new pathways for the diversification of the Fort Worth economy. In its first few years, the organization was funded by private organizations; however, currently various institutions like Texas Christian University, The University of Texas – Arlington, the University of North Texas Health Science Center- Fort Worth, City of Fort Worth, and corporate donors from all over the North Texas are funding the organization.
The aim of TechFW is to promote the development of the community through the commercialization of innovative technology to promote the regional entrepreneurs. ZS Pharma is one of the examples of TechFW success that partnered with TechFW after moving to Texas in 2010 to introduce a new drug to the market.
For more news on ZS Pharma see here:
[feed url=”http://bionews-tx.com/news/news-tags/zs-pharma/feed” number=”5″ ]
TechFW has introduced a variety of interventions like introducing companies and their products to the local service providers, arranging lab space for drug related operations, selection and identification of the team members of management and allocation of funds for the initial operations of the company. As a result of these efforts, ZS Pharma was able to raise over $70 million in funds and their lead product is currently in phase 3 clinical trials.